Advertisement
Dr. Chao's presentation, titled "L-DOS47: Targeting the TumorMicroenvironment with an Immunoconjugate" will provide a summary of selectedpreviously announced L-DOS47 research findings. "We are very pleased to havebeen invited to participate in this important scientific forum," said Dr.Chao. "It is an excellent opportunity to showcase our findings to Canada'sresearch community as we continue to advance our L-DOS47 development program.
Advertisement
For additional information on the Genomics and Health Initiativeconference, please visit: http://www.pbi.nrc.ca/ghi-agm.htm .
About L-DOS47
L-DOS47 combines Helix's proprietary DOS47 new drug candidate with ahighly specific single domain antibody, to form a potential new targeted drugproduct for the treatment of adenocarcinoma of the lung, the most common formof cancer in the world today. L-DOS47 is thought to function by leveraging anatural process in the body called the urea cycle, to produce an anti-cancereffect. It is based upon a naturally occurring enzyme called urease thatessentially reverses the urea cycle by breaking down urea into metabolitesthat include ammonia and hydroxyl ions. By doing so at the site of canceroustissues in the body, L-DOS47 is believed to modify the microenvironmentalconditions of lung cancer cells in a manner that leads to their death. Amongthese theorized effects, L-DOS47 is believed to stimulate an increase in thepH of the microenvironment surrounding the cancerous cells, effectivelyreversing the acidic extra-cellular conditions that are known to be necessaryfor cancer cell survival. As well, the local production of ammonia at the siteof cancerous tissues is thought to readily diffuse into the cancer cells toexert a potent cytotoxic effect by interfering with their critical metabolicfunctions.
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company specializing in thefield of cancer therapy. The Company is actively developing innovativeproducts for the prevention and treatment of cancer based on its proprietarytechnologies. Helix's product development initiatives include its TopicalInterferon Alpha- 2b and its novel L-DOS47 new drug candidate. Helix is listedon the TSX under the symbol "HBP".
Toronto and Frankfurt Stock Exchanges have not reviewed and do not acceptresponsibility for the adequacy or accuracy of the content of this NewsRelease. This News Release contains certain forward-looking statements andinformation regarding the Company's activities, which statements andinformation can be identified by the use of forward-looking terminology suchas "believed", "continue", "developing", "potential", or variations thereon,or comparable terminology referring to future events or results. Forwardlooking statements and information are statements and information about thefuture and are inherently uncertain. Helix's actual results could differmaterially from those anticipated in these forward-looking statements andinformation as a result of numerous risks and uncertainties including withoutlimitation: uncertainty whether L-DOS47 will be successfully developed andcommercialized as a drug or at all; the need for additional clinical trials,the occurrence and success of which cannot be assured; product liability andinsurance risks; research and development risks, the risk of technicalobsolescence; the need for further regulatory approvals, which ma
